Comparative Pharmacology
Head-to-head clinical analysis: PENBRITIN S versus PENICILLIN G SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENBRITIN S versus PENICILLIN G SODIUM.
PENBRITIN-S vs PENICILLIN G SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillinase-sensitive penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly/intravenously every 4-6 hours for moderate to severe infections.
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 7-10 hours in anuria).
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
Renal: 75-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~10%.
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic